These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 26482232)

  • 1. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.
    Leach AJ; Wigger C; Hare K; Hampton V; Beissbarth J; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
    BMC Pediatr; 2015 Oct; 15():162. PubMed ID: 26482232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines.
    Leach AJ; Wigger C; Beissbarth J; Woltring D; Andrews R; Chatfield MD; Smith-Vaughan H; Morris PS
    Int J Pediatr Otorhinolaryngol; 2016 Jul; 86():224-32. PubMed ID: 27260611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
    Beissbarth J; Wilson N; Arrowsmith B; Binks MJ; Oguoma VM; Lawrence K; Llewellyn A; Mulholland EK; Santosham M; Morris PS; Smith-Vaughan HC; Cheng AC; Leach AJ
    Vaccine; 2021 Apr; 39(16):2264-2273. PubMed ID: 33766422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine.
    Hare KM; Smith-Vaughan HC; Leach AJ; Pizzutto SJ; McCallum GB; Chang AB
    Vaccine; 2018 Mar; 36(13):1736-1742. PubMed ID: 29478754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules.
    Leach AJ; Wigger C; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
    BMC Pediatr; 2014 Aug; 14():200. PubMed ID: 25109288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 10-Valent pneumococcal non-typeable
    Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
    BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal vaccine impact on otitis media microbiology: A New Zealand cohort study before and after the introduction of PHiD-CV10 vaccine.
    Best EJ; Walls T; Souter M; Neeff M; Anderson T; Salkeld L; Ahmad Z; Mahadevan M; Walker C; Murdoch D; Mills N
    Vaccine; 2016 Jul; 34(33):3840-7. PubMed ID: 27265454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) in an Australian Indigenous paediatric population does not alter the prevalence of nontypeable Haemophilus influenzae without the protein D gene.
    Beissbarth J; Smith-Vaughan HC; Harris TM; Binks MJ; Leach AJ
    Vaccine; 2019 Jul; 37(30):4089-4093. PubMed ID: 31164306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    de Sévaux JL; Venekamp RP; Lutje V; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD001480. PubMed ID: 33231293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    Fortanier AC; Venekamp RP; Boonacker CW; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD001480. PubMed ID: 31135969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
    Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
    Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
    Karppinen S; Toivonen L; Schuez-Havupalo L; Teros-Jaakkola T; Waris M; Auranen K; Palmu AA; Peltola V
    Vaccine; 2019 May; 37(22):2935-2941. PubMed ID: 31027929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
    Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Wilson N; Arrowsmith B; Beissbarth J; Chatfield MD; Oguoma VM; Morris PS
    BMC Pediatr; 2021 Mar; 21(1):117. PubMed ID: 33685411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine.
    Casey JR; Adlowitz DG; Pichichero ME
    Pediatr Infect Dis J; 2010 Apr; 29(4):304-9. PubMed ID: 19935445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage.
    Clarke C; Bakaletz LO; Ruiz-Guiñazú J; Borys D; Mrkvan T
    Expert Rev Vaccines; 2017 Jul; 16(7):1-14. PubMed ID: 28571504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.
    Brandileone MC; Zanella RC; Almeida SCG; Brandao AP; Ribeiro AF; Carvalhanas TMP; Sato H; Andrade AL; Verani JR;
    Vaccine; 2016 Nov; 34(46):5604-5611. PubMed ID: 27692770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule.
    Wiertsema SP; Kirkham LA; Corscadden KJ; Mowe EN; Bowman JM; Jacoby P; Francis R; Vijayasekaran S; Coates HL; Riley TV; Richmond P
    Vaccine; 2011 Jul; 29(32):5163-70. PubMed ID: 21621576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carriage of Haemophilus influenzae is associated with pneumococcal vaccination in Italian children.
    Camilli R; Vescio MF; Giufrè M; Daprai L; Garlaschi ML; Cerquetti M; Pantosti A
    Vaccine; 2015 Aug; 33(36):4559-64. PubMed ID: 26190092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.